Forlong Biotechnology
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Clinical-stage biotech developing novel cytokine therapeutics for oncology using proprietary synthetic cytokine platforms.
Oncology
Technology Platform
Proprietary Fbody® long-acting/Fc engineering platform and Syntokine® synthetic cytokine platform designed to create optimized, next-generation cytokine therapeutics with improved pharmacokinetics and reduced toxicity.
Opportunities
The growing immuno-oncology market and renewed interest in cytokine therapeutics present a significant opportunity; successful clinical data for FL115 could lead to partnerships or advancement into broader solid tumor indications.
Risk Factors
As an early-stage, private company, Forlong faces clinical development risks, potential cytokine-related toxicity, and intense competition in the immuno-oncology space from larger, well-funded players.
Competitive Landscape
Competes with other cytokine-focused biotechs (e.g., Nektar, Alkermes, SOTIO) and large pharma immuno-oncology programs; differentiation relies on its proprietary Syntokine® platform to create optimized, long-acting cytokine analogs.